Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium.

Fonteyne V, Rammant E, Ost P, Lievens Y, De Troyer B, Rottey S, De Meerleer G, De Maeseneer D, De Ridder D, Decaestecker K.

Clin Genitourin Cancer. 2018 Aug 11. pii: S1558-7673(18)30241-6. doi: 10.1016/j.clgc.2018.07.026. [Epub ahead of print]

PMID:
30190222
3.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
4.

Pembrolizumab for the treatment of bladder cancer.

Sundahl N, Rottey S, De Maeseneer D, Ost P.

Expert Rev Anticancer Ther. 2018 Feb;18(2):107-114. doi: 10.1080/14737140.2018.1421461. Epub 2017 Dec 29.

PMID:
29284318
5.

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.

De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D, Ost P.

Radiat Oncol. 2017 Sep 22;12(1):157. doi: 10.1186/s13014-017-0893-x.

6.

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.

Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P.

J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3.

7.

Checkpoint inhibition: new treatment options in urologic cancer.

De Maeseneer DJ, Delafontaine B, Rottey S.

Acta Clin Belg. 2017 Feb;72(1):24-28. doi: 10.1080/17843286.2016.1260890. Review.

PMID:
28151378
8.

Parathyroid Adenoma Mimicking a Malignant Lymph Node on 18F-Choline PET-CT.

Van den Broeck B, De Maeseneer D, De Gersem R, De Man K.

Clin Nucl Med. 2017 Apr;42(4):e207-e209. doi: 10.1097/RLU.0000000000001550.

PMID:
28134691
9.

Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.

De Maeseneer DJ, Van Praet C, Lumen N, Rottey S.

Urol Oncol. 2015 Jul;33(7):310-21. doi: 10.1016/j.urolonc.2015.01.008. Epub 2015 Feb 21. Review.

PMID:
25708954
10.

A patient with progressive dyspnoea and a new heart murmur.

Vanderheeren P, De Maeseneer D, De Pauw M.

Acta Cardiol. 2014 Jun;69(3):322-4.

PMID:
25029882
11.

18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.

De Maeseneer DJ, Lambert B, Surmont V, Geboes K, Rottey SW.

Acta Clin Belg. 2010 Sep-Oct;65(5):291-9.

PMID:
21128554

Supplemental Content

Loading ...
Support Center